• Praxis Precision Medicines outlined expanded analyses from Phase 3 Essential3 program of ulixacaltamide for essential tremor, with results set for presentation at AAN 2026 in Chicago on April 18-22.
• Essential3 was described as first positive Phase 3 program in essential tremor, supporting FDA Breakthrough Therapy Designation for ulixacaltamide.
• Plenary presentation on April 21 will focus on durability of response from Essential3 Study 2, a randomized withdrawal trial.
• Poster presentations on April 20 will cover topline efficacy and safety outcomes from Essential3 Study 1, alongside a combined program analysis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604130800PRIMZONEFULLFEED9688206) on April 13, 2026, and is solely responsible for the information contained therein.